Recombinant Factor VIIa in Acute Intracerebral Haemorrhage "FAST"

Completed

Phase 3 Results

References

Related Links

Clinical Trials at Novo Nordisk

Sources for Trial Information

Novo Nordisk A/S
ClinicalTrials.gov

Staticmap?size=198x113&sensor=false&zoom=1&markers=1.28944, 103.85&markers=25.0911, 121.56&markers=13.7234, 100.476&markers=45.8228, 16.0221&markers=49.414, 8.67814&markers=32.0662, 34.7778&markers=1.2941, 103.783&markers=25.0421, 121.52&markers=-23.5489, -46.6388&markers=45.8149, 15.9785&markers=60.1698, 24.9382&markers=48.8566, 2.35222&markers=49.4019, 8.68029&markers=22.2479, 114.203&markers=32.0662, 34.7778&markers=43.1107, 12.3892&markers=59.3328, 18.0645&markers=39.1368, -84.5023&markers=39.9509, -75.1575&markers=13.7372, 100.538&markers=52.3702, 4.89517&markers=45.2858, -66.0493&markers=48.4224, -89.2662&markers=52.295, 4.96024&markers=-37.7881, 144

View Trial Locations

Recruitment

Enrollment: 829
Gender: Both
Minimum Age: 18 Years
Accepts Healthy Volunteers: No
104 locations, 22 countries

Principal Investigator

Nikolai C. Brun
Novo Nordisk
Brett Skolnick, PhD
Novo Nordisk
Global Clinical Registry (GCR, 1452)
Novo Nordisk A/S

NCT00127283 ClinicalTrials.gov →